Stock Events

Stock Events

Filana Therapeutics 

$0.6220
355
-$0.04-5.47%Friday 20:00
+$0.02+2.96%Friday 23:49After hours

Statistics

Day High
0.6585
Day Low
0.62
52W High
3.45
52W Low
0.6
Volume
214,783
Avg. Volume
2,019,795
Mkt Cap
30.05M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Dividends

0%Dividend Yield
Dec 2012
$5.25
Dec 2010
$2.00
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

Nov 11Expected
Q1 2026
Q2 2026
Next
-0.25
-0.22
-0.2
-0.18
Expected EPS
-0.245
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-90.97MNet Income

Analyst Ratings

$5.00Average Price Target
The highest estimate is ⁦5.00⁩.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow FLNA. It's not an investment recommendation.
Tesla
8
TSLA
Microsoft
5
MSFT
Amazon
5
AMZN
Alphabet
5
GOOGL

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap37.49B
Biogen is a leading competitor in the Alzheimer's treatment market, directly competing with Cassava's simufilam.
Lilly(Eli) &
LLY
Mkt Cap1.26T
Eli Lilly has developed donanemab, an Alzheimer's disease treatment, competing in the same space as Cassava Sciences.
Pfizer
PFE
Mkt Cap173.95B
Pfizer has a history of developing treatments for neurological disorders, including Alzheimer's, making it a competitor.
AC Immune SA
ACIU
Mkt Cap270.94M
AC Immune SA focuses on developing treatments for neurodegenerative diseases, including Alzheimer's, directly competing with Cassava.
Annovis Bio
ANVS
Mkt Cap50.36M
Annovis Bio operates in the Alzheimer's and Parkinson's disease space, making it a competitor to Cassava Sciences.
Anavex Life Sciences
AVXL
Mkt Cap168.71M
Anavex Life Sciences Corp. is working on treatments for Alzheimer's disease, competing in the same market as Cassava.

About

Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.
Show More
CEO
Richard Jon Barry
Employees
20
Country
United States
ISIN
US14817C1071
WKN
000A2PGL8

Listings

MX
MX
FLNA.MX
F
DE
PX91.F
STU
DE
PX91.STU
MU
DE
PX91.MU

0 Comments

Share your thoughts

FAQs

What is Filana Therapeutics stock price today?▼
The current price of FLNA is $0.62 USD — it has decreased by -5.47% in the past 24 hours. Watch Filana Therapeutics stock price performance more closely on the chart.
What is Filana Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Filana Therapeutics stocks are traded under the ticker FLNA.
What is Filana Therapeutics market cap?▼
Today Filana Therapeutics has the market capitalization of 30.05M
When is the next Filana Therapeutics earnings date?▼
Filana Therapeutics is going to release the next earnings report on November 11, 2026.
What were Filana Therapeutics earnings last quarter?▼
FLNA earnings for the last quarter are -0.18 USD per share, whereas the estimation was -0.23 USD resulting in a +20% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Filana Therapeutics revenue for the last year?▼
Filana Therapeutics revenue for the last year amounts to 0 USD.
What is Filana Therapeutics net income for the last year?▼
FLNA net income for the last year is -90.97M USD.
How many employees does Filana Therapeutics have?▼
As of November 2, 2026, the company has 20 employees.
In which sector is Filana Therapeutics located?▼
Filana Therapeutics operates in the Health & Wellness sector.
When did Filana Therapeutics complete a stock split?▼
The last stock split for Filana Therapeutics was on December 21, 2023 with a ratio of 14:10.
Where is Filana Therapeutics headquartered?▼
Filana Therapeutics is headquartered in AUSTIN, United States.